Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 13/20 | 0.51 |
| ▸ | AURKB | Q96GD4 | 6/20 | 0.51 |
| ▸ | ITK | Q08881 | 3/20 | 0.49 |
| ▸ | TTK | P33981 | 1/20 | 0.48 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.48 |
| ▸ | CDK8 | P49336 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6499706 | 0.88 | AURKA (0.50) | AURKAAURKBTTKMAPK8 | |
| SCHEMBL6509037 | 0.86 | TTK (0.57) | AURKAAURKBTTK | |
| SCHEMBL6507670 | 0.84 | TTK (0.45) | AURKAAURKBTTKMAPK8 | |
| SCHEMBL6506274 | 0.84 | EPHX2 (0.44) | AURKAAURKBTTKMAPK8 | |
| SCHEMBL6506793 | 0.83 | ROCK2 (0.48) | AURKAAURKBTTKMAPK8 | |
| SCHEMBL6504170 | 0.80 | ITK (0.48) | AURKAITK | |
| SCHEMBL6501248 | 0.80 | AURKA (0.43) | AURKAAURKBTTKMAPK8 | |
| SCHEMBL6503206 | 0.80 | MEN1 (0.44) | AURKATTKMAPK8 | |
| SCHEMBL7091365 | 0.79 | AURKA (0.65) | AURKAAURKBITKTTKMAPK8 | |
| SCHEMBL5372815 | 0.78 | MAP2K4 (0.56) | AURKAAURKBITKTTKMAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | GPR119, JAK3, IGF1R | AURKA 1439/4885AURKB 1065/4885ITK 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.